Panthera continues to sign up new clinical trials across its UK network of dedicated clinical trial sites

​

FOR MEDIA INFORMATION:

Simon Vane Percy

Vane Percy & Roberts

(M) +44 (0)7710 005 910

(T) +44 (0)1732 865 476

(E) simon@vanepercy.com

Tuesday 26^th January 2021

Panthera continues to sign up new clinical trials across its UK network of dedicated clinical trial sites

Panthera continues to sign up new contracts despite COVID -19. Unlike many other clinical trial sites, Panthera’s dedicated sites do not mix clinical trial patients with other patients minimizing the risk of COVID -19 infection for both patients and staff. Many research sites are based in NHS facilities which are focused on COVID.      

The latest win is a double-blind placebo trial involving refractory migraine patients who have at least four migraine days per month and failed between two and four previous migraine treatments in the last 10 years.

The trial is being run at Panthera’s Preston, North Manchester and North London sites where only clinical trial patients are seen. All Panthera’s sites have instituted strict contact SOPs and PPE requirements for both staff and patients to further reduce the risk of infection.

Panthera CEO Stuart Young “Unfortunately Covid-19 is not going to go away anytime soon. We are continuing to win contracts and support our clients in pharma and the CROs who recognise the effort we have made in making our sites as safe as possible for both staff and patients. We are committed to staying open as it is vital that we continue to help bring forward treatments which will help millions of patients.”

Panthera has found that patients are keen to become involved in clinical trials, which can provide health screening and face to face access to experienced clinicians at a time when access to local health care providers is stretched and is often only available through apps.

The comprehensive measures that have been put in place by Panthera cover the oncology trials, carried out in partnership with Rutherford’s four Cancer Centres and primary care based studies including vaccines, cardiac disease, osteoarthritis, osteoporosis, diabetes, allergies and migraine which are undertaken at Panthera’s three dedicated research clinics in Preston, North Manchester and North London.

About Panthera Biopartners – an Independent Site Management Organisation

Panthera Biopartners was founded by Dr Ian Smith – founder of Synexus - and Professor John Lyon – previously senior executive in Covance and serial entrepreneur - to provide CROs and pharma clients with services relating to the recruitment and running of clinical trials at customised clinical trial sites by GCP trained healthcare professionals.

Panthera has a growing network of sites across the UK managing studies in a variety of conditions in both primary care settings and hospital sites running trials in key secondary care conditions such as CNS, oncology and NASH with specialist investigators.

https://panthera-bio.com/

​

​